Heparin Differentially Regulates the Expression of Specific miRNAs in Mesenchymal Stromal Cells
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms252312589 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Michaela Oeller und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department for Transfusion Medicine, University Hospital of Salzburg (SALK), Paracelsus Medical University (PMU) Salzburg, Muellner Hauptstraße 48, 5…. Hauptthemen laut MEDLINE: MicroRNAs, Heparin, Mesenchymal Stem Cells, Cell Differentiation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bundesland Salzburg, WISS 2025 project ‘IDA-Lab Salzburg’, Land Salzburg.
Abstract (Originalsprache)
In regenerative medicine, stromal cells are supposed to play an important role by modulating immune responses and differentiating into various tissue types. The aim of this study was to investigate the influence of heparin, frequently used as an anticoagulant in human platelet lysate (HPL)-supplemented cell cultures, on the expression of non-coding RNA species, particularly microRNAs (miRNA), which are pivotal regulators of gene expression. Through genomic analysis and quantitative RT-PCR, we assessed the differential impact of heparin on miRNA expression in various stromal cell types, derived from human bone marrow, umbilical cord and white adipose tissue. Our results demonstrate that heparin significantly alters miRNA expression, with distinct up- and downregulation patterns depending on the original tissue source of human stromal cells. Furthermore, our analyses indicate that these heparin-induced alterations in miRNA expression profiles influence critical cellular processes, including proliferation, apoptosis and differentiation. In conclusion, our study highlights that heparin not only fulfills its primary role as an efficient anticoagulant but can also modulate important regulatory pathways in stromal cells by influencing miRNA expression. This may alter cellular properties and thus influence stromal cell-based therapeutic applications in regenerative medicine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department for Transfusion Medicine, University Hospital of Salzburg (SALK), Paracelsus Medical University (PMU) Salzburg, Muellner Hauptstraße 48, 5020 Salzburg, Austria.
- GMP Laboratory, PMU Salzburg, Strubergasse 21, 5020 Salzburg, Austria.
- Team Biostatistics and Big Medical Data, IDA Lab Salzburg, PMU Salzburg, Strubergasse 16, 5020 Salzburg, Austria.
- Research Program Biomedical Data Science, PMU Salzburg, Strubergasse 16, 5020 Salzburg, Austria.
- Department of Artificial Intelligence and Human Interfaces, Faculty of Digital and Analytical Sciences, Paris Lodron University Salzburg, Jakob Haringer Straße 2, 5020 Salzburg, Austria.
ORCID-Profile: Katharina Schallmoser, Eva Rohde, Sandra Laner-Plamberger
Förderung
- Bundesland Salzburg
- WISS 2025 project ‘IDA-Lab Salzburg’
- Land Salzburg
Zitieren
APA
Oeller, M., Schally, T., Zimmermann, G., Lauth, W., Schallmoser, K., Rohde, E., & Laner-Plamberger, S. (2024). Heparin Differentially Regulates the Expression of Specific miRNAs in Mesenchymal Stromal Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252312589
Vancouver
Oeller M, Schally T, Zimmermann G, Lauth W, Schallmoser K, Rohde E, et al. Heparin Differentially Regulates the Expression of Specific miRNAs in Mesenchymal Stromal Cells. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252312589
BibTeX
@article{Oeller2024,
author = {Oeller, Michaela and Schally, Tanja and Zimmermann, Georg and Lauth, Wanda and Schallmoser, Katharina and Rohde, Eva and Laner-Plamberger, Sandra},
title = {Heparin Differentially Regulates the Expression of Specific miRNAs in Mesenchymal Stromal Cells},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms252312589}
}
EUVIMED